BCL2L1 and non-small cell lung carcinoma: Last, we also provide further evidence to the efficacy of combined EGFR-TKI and BCL-xL-targeting BH3 mimetic [46] co-inhibitory strategy to dampen the emergence of early adaptive drug escape in EGFR-mutant NSCLC precision therapy.